Artificial Organs are associated to membrane based treatments clinically well established. They assure in extracorporeal blood circulation the metabolic functions of a failinf organ like the hemodialysers (HD) for the kidnwy or the membrane blood oxygenators (MBO) for the substitution of lungs during heart surgery. There are two major factors that needed to be address for the technical and medical progress of HDs and MBOs: 1) hemocompatibility of the membrane/blood interfaces, 2) enhancement of the flow management/mass transfer associated to the metabolic functions of the artificial kidney and lung.
The advancement of the state of art in hemocompatibility and mass transfer enhancement may bring health future benefits. This is only possible by bringing together an interdisciplinary team with expertise in Materials Science, Biomedical Engineering and Transport Phenomena.